I have stated many times that Europe is equal in market to the USA. Yet all our significant Adapt cash flow is from North America. We have EU approval for Adapt so why is it taking so long to get approval for a modified version i.e. Neo. What is our man in Europe doing? Why not send the Saint back to Europe to expedite the process. As well as Neo we have 3D. I will crack an expensive French champagne bottle when Admedus eventually sell Neo and or 3D products to Great Ormond Street Hospital whose clients include the elite of the Middle East who will not question the cost of our quality products.
I have stated many times that Europe is equal in market to the...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.13 |
Change
-0.220(1.20%) |
Mkt cap ! $352.7M | |||
| Open | High | Low | Value | Volume |
| $18.36 | $18.47 | $18.13 | $30.26K | 1.664K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12 | $18.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.35 | 48 | 2 |
View Market Depth
| Last trade - 10.32am 03/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |